Overview

Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response

Status:
Withdrawn

Trial end date:
2016-09-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to explore the effects of propranolol on social interaction, and secondarily on language, anxiety, adaptive behaviors, and global function in high functioning adults and adolescents with autism in a double-blinded, placebo-controlled pilot trial.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Missouri-Columbia

Treatments:

Propranolol

Criteria

Inclusion Criteria:

- For participants with autism: High-functioning, native-English speaking subjects with
ASD aged 15-30. High-functioning ASD is defined in this study by the DSM-V criteria
plus Autism Diagnostic Interview-Revised (ADI-R) criteria for Autism, and Wechsler
Abbreviated Scales of Intelligence (WASI) full scale IQ of at least 85.

Exclusion Criteria:

- For participants with autism: Non-autism learning disability (e.g. dyslexia),

- major psychiatric diagnosis (e.g. major depression, schizophrenia, bipolar disorder),

- other neurological diagnosis,

- major head trauma,

- any of the following exclusionary criteria related to propranolol (diabetes, reactive
airway/pulmonary disease, thyroid disease, bradyarrhythmias, unexplained syncope,
narrow angle glaucoma, pregnancy, known hypersensitivity/adverse reaction to
beta-blockers),

- any of the following exclusionary criteria related to placebo (severe allergy to
lactose),

- any of the following exclusionary criteria related to the psychophysiological
measurements (history of rash from adhesives).